Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProAgio with gemcitabine and nab-paclitaxel in metastatic pancreatic cancer
NCT06182072Phase 1Recruiting
- Sponsor
- ProDa BioTech
- Start
- Sep 2023
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of proagio in pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by ProDa BioTech. Primary endpoints: Safety of ProAgio combined with gemcitabine and nab-paclitaxel at 2 years, Patient Height at 2 years and 8 more. Started Sep 2023; status: recruiting.
02
Drugs
proagio
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06182072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182072.